Profile data is unavailable for this security.
About the company
ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The Company engages in developing various treatments that focuses on various mental health disorders. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder.
- Revenue in USD (TTM)277.00k
- Net income in USD-33.80m
- Incorporated2020
- Employees83.00
- LocationATAI Life Sciences NVWallstrasse 16Berlin 10179GermanyDEU
- Phone+49 8 921539035
- Fax+49 89 215390351
- Websitehttps://atai.life/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Century Therapeutics Inc | 1.37m | -133.47m | 258.48m | 152.00 | -- | 1.14 | -- | 188.67 | -2.22 | -2.22 | 0.0227 | 2.74 | 0.0034 | -- | -- | 9,013.16 | -33.17 | -- | -35.08 | -- | -- | -- | -9,742.41 | -- | -- | -- | 0.00 | -- | -57.01 | -- | -4.38 | -- | -- | -- |
| Emergent Biosolutions Inc | 1.19bn | -565.30m | 258.87m | 1.60k | -- | 0.3899 | -- | 0.2184 | -10.87 | -10.87 | 22.86 | 12.67 | 0.4988 | 1.99 | 6.09 | 740,875.00 | -23.79 | -2.94 | -38.89 | -3.66 | 41.19 | 53.24 | -47.69 | -5.95 | 0.5538 | 0.0636 | 0.5771 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
| TriSalus Life Sciences Inc | 21.98m | -68.07m | 259.10m | 112.00 | -- | -- | -- | 11.79 | -2.09 | -2.09 | 0.7291 | -1.31 | 1.17 | 1.26 | 7.49 | 196,276.80 | -339.18 | -- | -11,196.50 | -- | 86.74 | -- | -291.08 | -- | 0.714 | -16.82 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
| Agenus Inc | 161.42m | -239.61m | 259.34m | 389.00 | -- | -- | -- | 1.61 | -12.68 | -12.68 | 8.49 | -9.59 | 0.4823 | -- | 170.54 | 414,951.20 | -74.69 | -55.02 | -242.74 | -115.31 | 99.43 | -- | -154.88 | -102.92 | -- | -1.25 | -- | -- | 59.47 | 33.56 | -11.66 | -- | 22.58 | -- |
| ASP Isotopes Inc | 1.27m | -19.62m | 260.37m | 76.00 | -- | 23.24 | -- | 204.47 | -0.5335 | -0.5335 | 0.0344 | 0.2164 | 0.0425 | -- | -- | 16,755.00 | -65.49 | -- | -81.59 | -- | 32.81 | -- | -1,542.66 | -- | -- | -17.39 | 0.633 | -- | -- | -- | -229.34 | -- | -- | -- |
| Black Diamond Therapeutics Inc | 0.00 | -79.79m | 266.64m | 54.00 | -- | 2.39 | -- | -- | -1.70 | -1.70 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -57.38 | -40.29 | -64.24 | -43.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.57 | -- | -15.37 | -- |
| Caribou Biosciences Inc | 33.40m | -115.26m | 271.86m | 158.00 | -- | 0.7919 | -- | 8.14 | -1.45 | -1.45 | 0.4136 | 3.80 | 0.0886 | -- | 11.68 | 211,417.70 | -30.56 | -- | -33.02 | -- | -- | -- | -345.05 | -- | -- | -- | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
| ATAI Life Sciences NV | 277.00k | -33.80m | 272.87m | 83.00 | -- | 1.22 | -- | 985.10 | -0.24 | -0.24 | 0.0017 | 1.34 | 0.001 | -- | 0.0429 | 3,337.35 | -11.88 | -- | -12.80 | -- | -- | -- | -11,790.25 | -- | -- | -104.16 | 0.0809 | -- | 34.76 | -- | 73.60 | -- | -- | -- |
| Revance Therapeutics Inc | 236.65m | -313.72m | 278.88m | 534.00 | -- | -- | -- | 1.18 | -3.61 | -3.65 | 2.71 | -0.945 | 0.4482 | 1.87 | 10.46 | -- | -59.42 | -55.55 | -69.02 | -63.20 | 69.11 | -- | -132.57 | -304.96 | 4.64 | -30.79 | 1.30 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
| ESSA Pharma Inc | 0.00 | -27.73m | 279.49m | 50.00 | -- | 2.09 | -- | -- | -0.6282 | -0.6282 | 0.00 | 3.01 | 0.00 | -- | -- | 0.00 | -18.71 | -23.01 | -19.12 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
| Aquestive Therapeutics Inc | 51.50m | -28.77m | 279.49m | 135.00 | -- | -- | -- | 5.43 | -0.4273 | -0.4273 | 0.7836 | -0.4012 | 0.5398 | 2.78 | 6.49 | 381,496.30 | -30.15 | -76.63 | -43.46 | -123.85 | 60.23 | 64.24 | -55.85 | -102.95 | 5.85 | -3.51 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
| CorMedix Inc | 0.00 | -50.24m | 280.95m | 82.00 | -- | 4.84 | -- | -- | -0.9291 | -0.9291 | 0.00 | 1.06 | 0.00 | -- | -- | 0.00 | -78.96 | -54.84 | -88.88 | -62.32 | -- | 6.18 | -- | -18,323.42 | 6.41 | -- | 0.00 | -- | -100.00 | -- | -56.02 | -- | 46.27 | -- |
| Inozyme Pharma Inc | 0.00 | -77.11m | 282.06m | 59.00 | -- | 2.37 | -- | -- | -1.37 | -1.37 | 0.00 | 1.92 | 0.00 | -- | -- | 0.00 | -48.39 | -45.00 | -52.50 | -48.90 | -- | -- | -- | -- | -- | -- | 0.2748 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
| Inovio Pharmaceuticals Inc | 717.07k | -124.94m | 283.98m | 122.00 | -- | 2.71 | -- | 396.03 | -5.54 | -5.54 | 0.0317 | 4.04 | 0.0036 | -- | 0.5465 | 5,877.62 | -63.15 | -59.52 | -78.79 | -71.29 | -- | -- | -17,423.39 | -4,097.36 | -- | -- | 0.00 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
| Vanda Pharmaceuticals Inc. | 177.60m | -4.89m | 285.75m | 203.00 | -- | 0.5253 | -- | 1.61 | -0.0846 | -0.0846 | 3.08 | 9.35 | 0.2738 | 10.32 | 5.80 | 874,896.60 | -0.7538 | 6.61 | -0.8808 | 7.62 | 92.42 | 90.55 | -2.75 | 15.18 | 4.69 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
| Poseida Therapeutics Inc | 82.50m | -108.86m | 286.03m | 335.00 | -- | 3.38 | -- | 3.47 | -1.18 | -1.18 | 0.8907 | 0.8739 | 0.2864 | -- | 8.06 | 250,006.10 | -37.78 | -40.70 | -49.17 | -47.72 | -- | -- | -131.94 | -233.49 | -- | -12.88 | 0.4096 | -- | -50.42 | -- | -92.85 | -- | 19.01 | -- |
Data as of May 23 2024. Currency figures normalised to ATAI Life Sciences NV's reporting currency: US Dollar USD
5.35%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Millennium Management LLCas of 31 Mar 2024 | 2.22m | 1.34% |
| Morgan Stanley Investment Management, Inc.as of 31 Mar 2024 | 1.69m | 1.02% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 895.19k | 0.54% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 880.30k | 0.53% |
| Marshall Wace LLPas of 31 Mar 2024 | 793.84k | 0.48% |
| Brown University Investment Officeas of 31 Mar 2024 | 718.50k | 0.43% |
| BlackRock Advisors (UK) Ltd.as of 31 Mar 2024 | 518.17k | 0.31% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 413.78k | 0.25% |
| Two Sigma Investments LPas of 31 Mar 2024 | 400.99k | 0.24% |
| Fiduciary Trust International LLCas of 31 Mar 2024 | 356.36k | 0.22% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
